vpm2014 A Cardialysis Event

PROGRAM of the Vulnerable Patient Meeting

June 22, 2014 -Day 1-

08:00 - 08:15 Welcome: Board of directors (Prof. Serruys, Prof. Stone, Prof. van der Steen, Prof. Koenig, Prof. Lerman, Dr. Garcia-Garcia and Dr. van Es)

08:15 - 09:30	Opening lectures: Patrick W. Serruys and Gregg Stone
08:15 - 08:30	Humoral immunity in atherosclerosis - from mechanisms to biomarkers Dorian O Haskard (UK)
08:30 - 08:45	Assessing NON invasively coronary anatomy and physiology information - finding the vulnerable patient Carlos Rochitte (BR)
08:45 - 09:00	Assessing invasively coronary anatomy and physiology information - finding the vulnerable plaque Fernando Alfonso (SPA)
09:00 - 09:15	Are imaging endpoints appropriate replacement of hard endpoints clinical trials?
09:15 - 09:30	Jagat Narula (USA) Why did the secretory phospholipase A2 inhibitors failed? Robert Rosenson (USA)
09:30 - 10:00	Discussion
10:00 - 12:00	Basic science session: Renu Virmani / Jagat Narula
10:00 - 10:10	Monoclonal antibodies against ox-LDL Dorian O Haskard (UK)
10:10 - 10:12	Q&A
10:12 - 10:22	Macrophage differentiation prevents foam cell formation in atherosclerotic plaques
10:22 - 10:25	Renu Virmani (USA) Q&A
10:25 - 10:35	Reversal of plaque hypoxia reduces its necrotic core size Mat Daemen (NL)
10:35 - 10:37 10:37 - 10:47	Q&A Fractional flow reserve and inflammatory markers
10.37 - 10.47	Imo Hoefer (NL)
10:47 – 10:49	Q&A
10:49 – 10:59	Targeting of mannose receptors in atherosclerosis? Jagat Narula (USA)
10:59 - 11:01	Q&A
11:01 - 11:11	The mitochondria as a therapeutic target in ischemia Lilach Lerman (USA)
11:11-11:13	Q&A
11:13 – 11: 43	Discussion

11:43 - 12:20 Coffee break



PROGRAM of the Vulnerable Patient Meeting

June 22, 2014 -Day 1-

12:20 - 13:30	Biomechanics session: Peter Stone and Ton van der Steen
12:20 - 12:30	Shear stress and atherosclerosis Jolanda Wentzel (NL)
12:30 - 12:32	Q&A
12:32 - 12:42	Mechanics of the coronary plaque Frank Gijsen (NL)
12:42 - 12:44	Q&A
12:44 - 12:54	The Prediction trial: subgroup analysis Peter Stone (USA)
12:54 - 12:56	Q&A
12:56 - 13:30	Discussion
13:30 - 15:18	Lunch break
15:18 - 17:00	Identifying the vulnerable patient assessing: Amir Lerman and Gregg Stone
15:18 - 15:28	Cardiac CT Angiography to Predict Future Acute Coronary Syndromes Mat Daemen (NL)
15:28 - 15:30	Q&A
15:30 - 15:40	Developments in non-invasive coronary plaque imaging: MRI Carlos Rochitte (BR)
15:40 - 15:42	Q&A
15:42 - 15:52	Do plaques enlarge before resulting in an event? Jagat Narula (USA)
15:52 - 15:54	Q&A
15:54 - 16:04	Imaging of early coronary atherosclerosis Amir Lerman (USA)
16:04 - 16:06	Q&A
16:06 - 16:16	Mendelian randomization David Swerdlow (UK)
16:16 - 16:18	Q&A
16:18 - 16:28	Conventional and novel biomarkers: overview Domique de Kleijn (Sing)
16:28 - 16:30	Q&A
16:30 - 17:00	Discussion



PROGRAM of the Vulnerable Patient Meeting

June 23, 2014 -Day 2-

08:00 - 09:30	Invasive imaging 1: Ton van der Steen and Hector Garcia
08:00 - 08:10	Photoacoustics
	Ton van der Steen (NL)
08:10 - 08:12	Q&A
08:12 - 08:22	Intravascular imaging in animal studies: what are the surrogates that we could image
	Robert Wilensky (USA)
08:22 - 08:24	Q&A
08:24 - 08:34	Micro-OCT tissue characterization Gary Tearney (USA)
08:34 - 08:36	Q&A
08:36 - 08:46	Tissue vessel characterization – lipid and collagen detection Jim Goldstein (USA)
08:46 - 08:48	Q&A
08:48 - 08:58	High Frequency IVUS – 50 MHz
	Tom Moore (USA)
08:58 - 09:00	Q&A
09:00 – 09:10	Validation of virtual histology in human coronary arteries
	Salvatore Brugaletta (SPA)
09:10 - 09:30	Discussion
09:30 - 10:50	Invasive Imaging 2: Patrick W. Serruys and Fernando Alfonso
09:30 - 09:40	High speed OCT
	Gijs van Soest (NL)
09:40 - 09:42	Q&A
09:42 - 09:52	OCT imaging of the VP lesions beyond the culprit lesion Evelyn Regar (NL)
09:52 - 09:54	Q&A
09:54 - 10:04	OCT-Based Diagnosis and Management of STEMI Associated With Intact Fibrous Cap
	Francesco Prati (It)
10:04 - 10:06	Q&A
10:06 - 10:16	2-D and 3-D OCT for assessment of thrombus: insights from TROFI study Hector Garcia (NL)
10:16 - 10:18	Q&A
10:18 - 10:50	Discussion

10:50 - 11:10 Coffee break

vpm2014 A Cardialysis Event

PROGRAM of the Vulnerable Patient Meeting

June 23, 2014 -Day 2-

11:10 - 12:50	"Future Therapeutic Options for Targeting Atherosclerosis" – Wolfgang Koenig and Hector Garcia
11:10 - 11:20	Testing the inflammation hypothesis: The CANTOS Study (IL-1 β AB) Wolfgang Koenig (GER)
11:20 - 11:22	Q&A
11:22 - 11:32	Biotechnology is coming to the CV field: a near future perspective Giovanni Sperti(ITA)
11:32 - 11:34	Q&A
11:34 - 11:44	iPCSK9: The RNA interference approach David Kallend (CH)
11:44 - 11:46	Q&A
11:46 - 11:56	The HDL hypothesis under question: Basic science and related clinical studies <i>Eric Stroes (NL)</i>
11:56 - 11:58	Q&A
11:58 - 12:08	MDCO-216: The return of Apo-A1 Milano David Kallend (CH)
12:08 - 12:10	Q&A
12:10 - 12:20	Phase II and III pending clinical trial data with phospholipase A2 inhibitors Robert Rosenson (USA)
12:20 - 12:22	Q&A
12:22 - 12:50	Discussion
12:50 - 14:50	Lunch
14:50 - 16:10	PROSPECT II: Fernando Alfonso and Jagat Narula
14:50 - 15:00	Bioabsorbable scaffolds technology, bench testing and animal results: is it a good alternative for local passivation Richard Rapoza (USA)
15:00 - 15:10	Bioabsorbable scaffolds – clinical experience Michael Maeng (DEN)
15:10 - 15:25	ATHEROREMO IVUS and NIRS natural history study and recapping of the cap concept Patrick W. Serruys (NL)
15:25 - 15:40	PROSPECT II study design Gregg Stone (USA)
15:40 - 16:10	Q&A
16:10 - 16:30	Coffee break



PROGRAM of the Vulnerable Patient Meeting

16:30 - 17:42	Clinical Trials in atherosclerosis: John Ambrose and Gregg Stone
16:30 - 16:40	SELECT-ACS, MODIFY, CAIN-3 and CHI-SQUARE studies Philippe L'Allier (CAN)
16:40 - 16:42	Q&A
16:42 - 16:52	Near-infrared Spectroscopic Findings in STEMI and Other Coronary Syndromes
	Jim Muller (USA)
16:52 - 16:54	Q&A
16:54 - 17:04	YELLOW and VERDICT studies
	Akiko Maehara (USA)
17:04 - 17:06	Q&A
17:06 - 17:30	Discussion
17:30 - 17:40	VP assessment in the future
	John Ambrose (USA)
17:40 - 17:42	Q&A

17:42 - 18:00 Closing remarks: Patrick W. Serruys, Amir Lerman, Wolfgang Koenig and Gregg Stone, Gerrit-Anne van Es, Ton van der Steen and Hector Garcia